A Randomized, Open-Label, Parallel-Designed, Phase I Clinical Study to Evaluate the Pharmacokinetics Similarity of Single-Dose CBP-201 Injection With Different Dosage Forms and Strengths in Healthy Adult Chinese Subjects

This is a single-center, randomized, open-label, single-dose, parallel-designed PK similarity study.

Start Date18 Jul 2023

Sponsor / Collaborator

Suzhou Connect Biopharma Co. Ltd.

NCT05905133 / Active, not recruitingPhase 2

A Multi-Center, Single-Arm, Open-Label Clinical Study to Evaluate the Safety and Efficacy of CBP-201 in Chinese Adult Subjects With Moderate to Severe Atopic Dermatitis

This study is a single-arm, open-label, multi-center clinical study designed to assess the safety and efficacy of CBP-201 in eligible subjects with moderate to severe Atopic Dermatitis.

Start Date15 Jul 2023

Sponsor / Collaborator

Suzhou Connect Biopharma Co. Ltd.

CTR20231708 / CompletedPhase 1

一项在中国健康成年受试者中评价不同规格剂型的CBP-201注射剂药代动力学相似性的随机、开放、单剂量、平行设计的I期临床研究

[Translation] A randomized, open-label, single-dose, parallel-design phase I clinical study to evaluate the pharmacokinetic similarity of different dosage forms of CBP-201 injection in healthy Chinese adult subjects

评价中国健康成年受试者单次皮下给予不同规格剂型的CBP-201注射剂（CBP-201注射液（预灌封）（150mg（1mL）/支）、CBP-201注射液（预灌封）（300mg（2mL）/支）、CBP-201注射液（150mg（1mL）/瓶））的药代动力学（PK）相似性。

[Translation]

To evaluate the pharmacokinetic (PK) similarity of different strengths of CBP-201 injection (CBP-201 injection (prefilled) (150 mg (1 mL)/vial), CBP-201 injection (prefilled) (300 mg (2 mL)/vial), and CBP-201 injection (150 mg (1 mL)/vial)) after a single subcutaneous administration to healthy Chinese adult subjects.

Start Date14 Jul 2023

Sponsor / Collaborator

Suzhou Connect Biopharma Co. Ltd.

100 Clinical Results associated with Rademikibart

100 Translational Medicine associated with Rademikibart

100 Patents (Medical) associated with Rademikibart

Literatures (Medical) associated with Rademikibart

01 Dec 2023·Dermatology and therapy

A Mini Review of the Impact of Baseline Disease Severity on Clinical Outcomes: Should We Compare Atopic Dermatitis Clinical Trials?

Review

Author: Collazo, Raúl ; Silverberg, Jonathan I ; Ho, Selwyn

Based on clinical trials of systemic treatments in adults with moderate-to-severe atopic dermatitis (AD) reported between 2014 and 2023, we used linear regression to investigate relationships between baseline Eczema Area and Severity Index (EASI) scores and (1) study start date, (2) EASI response, and (3) rescue medication rates. Analysis 1 was conducted with all patients from monotherapy and combination therapy trials; analyses 2 and 3 used monotherapy trial placebo arms. Across 32 trials with a baseline inclusion criterion of EASI ≥ 16, baseline mean EASI scores decreased with study start date. The lowest and highest baseline mean EASI scores were 25.1 and 33.6 (median 21.1 and 30.5), reported for the WW001 Phase 2 trial of rademikibart (formerly CBP-201; start date, July 2020) and the SOLO1 Phase 3 trial of dupilumab (start date, December 2014), respectively. In placebo arms, lower baseline EASI scores tended to be associated with greater percent reductions in EASI scores at Week 16 and less rescue medication usage. The WW001 trial placebo arm had the lowest baseline EASI score (mean 25.2; median 22.1), lowest rescue medication rate (14.3%), and a large reduction in least squares mean EASI scores (- 39.7%) at Week 16. In summary, baseline mean EASI scores have decreased across clinical trials conducted during the last decade. Less severe AD at baseline tended to be associated with greater placebo response and less use of rescue medications in placebo arms. Intertrial differences in variables, such as baseline AD severity, limit the validity of indirectly comparing clinical trials.

01 Dec 2023·Clinical and translational science

Rademikibart (CBP‐201), a next‐generation monoclonal antibody targeting human IL‐4Rα: Two phase I randomized trials, in healthy individuals and patients with atopic dermatitis

Article

Author: Spelman, Lynda ; Yang, Xin ; Sansone, Kenneth J ; Wang, Junying ; White, Jeffery ; Wei, Zheng ; Pan, Wubin ; Sinclair, Rodney

Abstract:

IL‐4 and IL‐13 signaling via IL‐4Rα plays key roles in the pathogenesis of atopic dermatitis (AD) and asthma. Rademikibart (formerly CBP‐201), a next‐generation human IgG4 kappa monoclonal antibody, blocks IL‐4Rα‐mediated signal transduction. We performed two phase I, randomized, double‐blind, placebo‐controlled trials. In a single‐ascending dose trial, 40 healthy adults were randomized 3:1 to rademikibart (75–600 mg s.c., 300 mg i.v.) or placebo, with 12 weeks of follow‐up. In the multiple‐ascending dose trial, 31 adults with moderate‐to‐severe AD were randomized 4:1 to once weekly rademikibart (75–300 mg s.c.) or placebo for 4 weeks, plus 7 weeks of follow‐up. Most treatment‐emergent adverse events (TEAEs) were mild; none were serious. Two s.c. injection site reactions and one TEAE of conjunctivitis were reported, all were mild. Rapid and sustained improvements were observed in AD severity and in quality of life (QoL), without plateauing. At week 4, efficacy scores improved by a maximum of −74.4% (Eczema Area and Severity Index), −62.7% (body surface area), −52.8% (Pruritus Numerical Rating Scale [PNRS] severity), −54.4% (PNRS frequency), and − 69.9% (Dermatology Life Quality Index). Thymus activation regulated chemokine inflammatory biomarker concentrations decreased in both trials (−55.4% in the pooled rademikibart arms vs. +18.0% with placebo, at week 5, in patients with AD). Exposure to rademikibart increased in a greater than dose‐proportional manner, suggesting nonlinear clearance. In summary, rademikibart was well‐tolerated and associated with rapid and sustained improvements in eczematous lesions, pruritus, QoL, and inflammatory biomarker concentrations during 4 weeks of treatment. Efficacy responses did not plateau and were generally dose dependent. These promising findings support further development of rademikibart in patients with AD.

01 Apr 2024·The Journal of allergy and clinical immunology

Efficacy and safety of rademikibart (CBP-201), a next-generation mAb targeting IL-4Rα, in adults with moderate to severe atopic dermatitis: A phase 2 randomized trial (CBP-201-WW001)

Article

Author: Pan, Wubin ; Ho, Selwyn ; Song, Jing ; Silverberg, Jonathan I ; Strober, Bruce ; Wei, Zheng ; Li, Pauline ; Guo, Jiawang ; Yun, Jang ; Xu, Jinhua ; Simpson, Eric L ; Guttman-Yassky, Emma ; Collazo, Raúl ; Longphre, Malinda ; Williams, Belinda ; Feinstein, Brian

BACKGROUND:

Rademikibart (CBP-201) is a next-generation IL-4 receptor alpha-targeting antibody.

OBJECTIVE:

We sought to evaluate rademikibart in adults with moderate to severe atopic dermatitis.

METHODS:

A total of 226 patients were randomized, double-blind, to subcutaneous rademikibart (300 mg every 2 weeks [Q2W], 150 mg Q2W, 300 mg every 4 weeks [Q4W]; plus 600-mg loading dose) or placebo. Randomization began in July 2020. The trial was completed in October 2021.

RESULTS:

The WW001 phase 2 trial achieved its primary end point: significant percent reduction from baseline in least-squares mean Eczema Area Severity Index (EASI) to week 16 with rademikibart 300 mg Q2W (-63.0%; P = .0007), 150 mg Q2W (-57.6%; P = .0067), 300 mg Q4W (-63.5%; P = .0004) versus placebo (-39.7%). EASI scores decreased significantly with 300 mg Q2W and Q4W at the earliest assessment (week 2), with no evidence of plateauing by week 16. Significant improvements were also observed in secondary end points, including pruritus. Across the primary and secondary end points, efficacy tended to be comparable with 300 mg Q2W and Q4W dosing. Rademikibart and placebo had similar, low incidence of treatment-emergent adverse events (TEAEs) (48% vs 54%), serious TEAEs (1.8% vs 3.6%), TEAEs leading to treatment discontinuation (1.2% vs 1.8%), conjunctivitis of unspecified cause (2.9% vs 0%), herpes (0.6% vs 1.8%), and injection-site reactions (1.8% vs 1.8%). Although no discontinuations were attributed to coronavirus disease 2019, pandemic-related restrictions likely had an impact on trial conduct.

CONCLUSIONS:

Rademikibart was efficacious and well tolerated at Q2W and Q4W intervals. Q4W dosing is a more convenient frequency than approved for current therapies.

News (Medical) associated with Rademikibart

12 Jun 2024

·www.globenewswire.com

Connect Biopharma Announces New Leadership and Chair of the Board of Directors

Industry leader Barry Quart, Pharm.D. appointed as Chief Executive Officer succeeding Zheng Wei, Ph.D., who will remain on the Board of Directors and serve as an advisor to assist with the transitionExperienced life science executive David Szekeres appointed as PresidentKleanthis G. Xanthopoulos, Ph.D. appointed as Chair of the Board of Directors SAN DIEGO, CA and TAICANG, China, June 12, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (Connect or the Company), a U.S.-headquartered, global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today the appointments of Barry Quart, Pharm.D., as Chief Executive Officer (CEO) and Director, David Szekeres as President, and Kleanthis G. Xanthopoulos, Ph.D., as the new Chair of the Board of Directors (Board). Dr. Xanthopoulos, currently the lead independent member of the Board since 2022, has been appointed Chair of the Board. Dr. Xanthopoulos succeeds Wubin (Bill) Pan, Ph.D., M.B.A., who will remain on the Board and serve as an advisor to the Company during the transition. “On behalf of the board and the Connect team I would like to thank Drs. Zheng Wei and Wubin (Bill) Pan, who co-founded Connect with the vision to bring next-generation therapeutics to patients with inflammatory diseases and improve their lives. We are grateful for their contributions and unwavering commitment to the Connect mission by building an outstanding organization with Phase 3-ready programs and a robust pipeline,” said Kleanthis G. Xanthopoulos, Ph.D., Chair of the Board of Directors of Connect. “The highly differentiated data generated from positive readouts in both asthma and atopic dermatitis for the lead asset, rademikibart, establishes Connect now as a U.S.-driven late-stage company entering its pre-commercial phase. I am thrilled to welcome the new leadership team with such an impressive track record and eager to leverage Barry’s and David’s operational expertise and wealth of experience to unlock the maximum potential/value of rademikibart and the rest of the pipeline.” "Founding and leading Connect with Bill and working with many talented colleagues who are passionate about discovery and development of life-changing medicines in the past 12 years has been a true honor and privilege," said Dr. Zheng Wei. "As Connect evolved to focus on advancing rademikibart, Bill and I look forward to supporting Barry and David as Connect enters an exciting new phase." Dr. Barry Quart, the Company’s newly appointed CEO, brings over 30 years of extensive experience serving in leadership positions in biotechnology and pharmaceutical companies and developing innovative pharmaceutical products. He has personally led several early-stage biotech companies through late-stage clinical development and regulatory strategy, highlighted by nine U.S. Food and Drug Administration (FDA) approved drugs. “I am honored to assume the CEO role for Connect and to join the Board. I am incredibly excited about the potential of the Company going forward with rademikibart, which I believe to be a best-in-class competitor to dupilumab,” said Barry Quart, Pharm.D., CEO and Director of Connect. “With the multiple innovative therapies in our pipeline, a cash runway into at least 2026, and an expanded management team with proven experience in the U.S., I believe we have all the elements in place to achieve significant shareholder returns in the future.” Dr. Quart was most recently CEO at Heron Therapeutics. He first served as CEO and Director starting in 2012, transitioned to President and CEO in 2019 and was named Chair of the Board in October 2020. At Heron, Dr. Quart oversaw the development and approval of four drugs: two drugs for CINV (CINVANTI® and SUSTOL®) and two acute care drugs (ZYNRELEF® and APONVIE®). Prior to Heron, Dr. Quart co-founded Ardea Biosciences, Inc. in 2006 and served as its President and Chief Executive Officer and Director from its inception through its acquisition by AstraZeneca PLC in 2012. At Ardea, Dr. Quart invented and oversaw the development of a drug for gout (ZURAMPIC®), as well as the design and development of a series of MEK inhibitors for cancer that were licensed to Bayer AG. Dr. Quart currently serves on the Board of Directors of Kiniksa Pharmaceuticals. He is an inventor on 18 U.S. patents and an author on 75 publications and abstracts. Dr. Quart received his Pharm.D. from the University of California, San Francisco. David Szekeres is an experienced life science executive with a proven track record of creating value with deep operational, commercial, corporate development/strategy, and legal expertise. Mr. Szekeres was most recently Executive Vice President and Chief Operating Officer of Heron Therapeutics. Prior to Heron, he was the Chief Business Officer and General Counsel of Regulus Therapeutics, a clinical-stage biotech company focused on RNA therapeutics and the Head of Mergers & Acquisitions at Life Technologies Corporation. Mr. Szekeres also holds positions as the Chair of the Board of GRI Bio, Inc. (Nasdaq: GRI) and is a member of the Board of Directors of CureMatch, Colossal Biosciences, and the Sanford Burnham Prebys Medical Discovery Institute. He received his J.D. from Duke University School of Law and earned his B.A. at the University of California, Irvine. About Connect Biopharma Holdings Limited Connect Biopharma is a global, clinical-stage biopharmaceutical company applying its expertise in T cell biology and deep knowledge of the drug discovery industry to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis and asthma. The Company’s second product candidate, icanbelimod (formerly known as CBP-307), is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). For more information, please visit: https://www.connectbiopharm.com/ Forward-Looking Statements Connect Biopharma cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may”, “could”, “will”, “would”, “should”, “expect”, “plan”, “anticipate”, “believe”, “estimate”, “intend”, “predict”, “seek”, “contemplate”, “look forward”, “potential”, “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. These statements include the Company’s plans to advance the development of its product candidates, the timing of achieving any development, regulatory or commercial milestones or reporting data or whether such milestones or data will be achieved or generated, including whether any new drug application will be submitted or accepted and the timing thereof, and the potential of such product candidates, including to achieve any benefit, improvement, differentiation, trend or profile or any product approval or be effective, and the sufficiency of the Company’s cash and investments to support planned operations. The inclusion of forward-looking statements should not be regarded as a representation by Connect Biopharma that any of its plans will be achieved. Actual data may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the Securities and Exchange Commission (SEC), including the Company’s Annual Report on Form 20-F filed with the SEC on April 16, 2024, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Connect Biopharma undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks is included in Connect Biopharma’s filings with the SEC which are available from the SEC’s website (www.sec.gov) and on Connect Biopharma’s website (www.connectbiopharm.com) under the heading “Investors.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. INVESTOR CONTACT:Tim McCarthyLifeSci Advisorstim@lifesciadvisors.com

Executive ChangeAcquisition

23 May 2024

·www.globenewswire.com

Connect Biopharma Presents Late-Breaking Abstract at the American Thoracic Society 2024 International Conference on the Positive Rademikibart Data from its Global Phase 2b in Patients with Moderate-to-Severe Asthma

Rademikibart treatment significantly improved lung function at Week 12; improvements were observed as early as Week 1 and sustained through Week 24 Significant improvement in patient-reported asthma control occurred early and was sustained through Week 24 End of Phase 2 (EoP2) meeting is scheduled with the U.S. Food and Drug Administration (FDA) for Q2 2024 May 22, 2024 -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, announced today that Edward Kerwin, M.D. presented a late-breaking poster presentation on the positive results from the rademikibart global Phase 2b trial in patients with moderate-to-severe asthma at the American Thoracic Society (ATS) 2024 International Conference, taking place May 17-22, 2024 in San Diego, CA. “We are excited Dr. Kerwin shared the highly compelling results of our global Phase 2b study in asthma showing clinically meaningful and sustained improvement in lung function and asthma control with pulmonary experts at this year’s meeting,” commented Zheng Wei, Ph.D., Co-Founder and CEO of Connect Biopharma. “We are preparing for the End-of-Phase 2 meeting with the FDA for asthma in Q2 2024, and look forward to providing an update on next steps following the completion of this important meeting.” The presentation, titled “Improved Lung Function and Asthma Control Observed with Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma (CBP-201-WW002)”, highlighted results from the Phase 2b trial announced in December 2023 that showed that both doses of rademikibart led to significant improvements in pre-bronchodilator (BD) forced expiratory volume over one second (FEV1) at Week 12 with both rademikibart doses. Furthermore, the significant improvements seen compared to placebo with rademikibart started as early as Week 1 and were sustained through 24 weeks of treatment. A predefined exploratory analysis showed further improvement in lung function was achieved in patients with eosinophil levels of ≥300 cells/µl. A significant improvement in patient-reported asthma control occurred rapidly and was sustained through 24 weeks of treatment. Additionally, although the study was not powered to detect differences in exacerbations between the treatment groups, strong trends for reductions in annualized exacerbations of approximately 50% and prolonged time to exacerbation were observed. The Company has scheduled an EoP2 meeting with the FDA to discuss rademikibart’s Phase 3 regulatory path in Q2 2024. A copy of the poster presentation will be made available on Connect Biopharma’s website under the “Our Science” section. Connect Biopharma is a global, clinical-stage biopharmaceutical company applying its expertise in T cell biology and deep knowledge of the drug discovery industry to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. The Company’s second product candidate, icanbelimod (formerly known as CBP-307), is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). For more information, please visit: https://www.connectbiopharm.com/ The content above comes from the network. if any infringement, please contact us to modify.

Clinical ResultImmunotherapyCell Therapy

07 May 2024

·www.globenewswire.com

Connect Biopharma to Present a Late-Breaking Abstract at the American Thoracic Society (ATS) 2024 International Conference on the Positive Results from the Global Phase 2b Trial of Rademikibart in Patients with Moderate-to-Severe Asthma

SAN DIEGO, CA and TAICANG, China, May 07, 2024 (GLOBE NEWSWIRE) -- Connect Biopharma Holdings Limited (Nasdaq: CNTB) (“Connect Biopharma” or the “Company”), a global clinical-stage biopharmaceutical company dedicated to improving the lives of patients with chronic inflammatory diseases through the development of therapies derived from T cell-driven research, today announced data from its global Phase 2b trial of rademikibart in patients with moderate-to-severe asthma was accepted as a late-breaking abstract for poster presentation at the upcoming ATS 2024 International Meeting being held May 17-22, 2024 in San Diego, CA. Poster Presentation Details: Title: Improved Lung Function and Asthma Control Observed with Rademikibart in Patients with Moderate-to-Severe Uncontrolled Asthma (CBP-201-WW002) Presenter: Edward Kerwin, M.D. Session: Poster Discussion D21: Terminator: Control of Airway Inflammation and Immune Response in Asthma Session Date and Time: Wednesday, May 22, 2024 at 8:15 AM – 10:15 AM PT Location: San Diego Convention Center, Room 31A-C (Upper Level) Additionally, the poster presentation will be available as an ePoster on the ATS 2024 International Conference website, and will be available for viewing May 19 - 22, 2024. About Connect Biopharma Holdings Limited Connect Biopharma is a global, clinical-stage biopharmaceutical company applying its expertise in T cell biology and deep knowledge of the drug discovery industry to develop innovative therapies to treat chronic inflammatory diseases with the goal of improving the lives of millions of those affected around the world. The Company is building a rich pipeline of proprietary small molecules and antibodies, using functional T cell assays, to screen and discover potent product candidates against validated immune targets. The Company’s lead product candidate, rademikibart (formerly known as CBP-201), is an antibody designed to target interleukin-4 receptor alpha (IL-4Rα) in development for the treatment of atopic dermatitis (AD) and asthma. The Company’s second product candidate, icanbelimod (formerly known as CBP-307), is a modulator of S1P1 T cell receptors and is in development for the treatment of ulcerative colitis (UC). For more information, please visit: https://www.connectbiopharm.com/ INVESTOR CONTACT: Tim McCarthy LifeSci Advisors tim@lifesciadvisors.com

Phase 2Clinical ResultImmunotherapyCell Therapy

100 Deals associated with Rademikibart

R&D Status

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Asthma	Phase 3	CN	Suzhou Connect Biopharma Co. Ltd.	26 Jun 2024
Dermatitis, Atopic	Phase 3	-	Suzhou Connect Biopharma Co. Ltd.	01 Dec 2022
Nasal Polyps	Phase 2	US	Suzhou Connect Biopharma Co. Ltd.	22 Jul 2021
Nasal Polyps	Phase 2	BE	Suzhou Connect Biopharma Co. Ltd.	22 Jul 2021
Nasal Polyps	Phase 2	PL	Suzhou Connect Biopharma Co. Ltd.	22 Jul 2021
Nasal Polyps	Phase 2	ES	Suzhou Connect Biopharma Co. Ltd.	22 Jul 2021
Nasal Polyps	Phase 2	UA	Suzhou Connect Biopharma Co. Ltd.	22 Jul 2021
Chronic rhinosinusitis with nasal polyps	Phase 2	US	Suzhou Connect Biopharma Co. Ltd.	16 Jun 2021
Chronic rhinosinusitis with nasal polyps	Phase 2	CN	Suzhou Connect Biopharma Co. Ltd.	16 Jun 2021
Chronic rhinosinusitis with nasal polyps	Phase 2	PL	Suzhou Connect Biopharma Co. Ltd.	16 Jun 2021

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT05017480 (CTgov)	Phase 2	Dermatitis, Atopic	330	CBP-201 (Group A: CBP-201 300mg Q2W)	ohrwbwktyj(wrbmvjtskq) = ldxpliupnk qkrtvwcsgm (ftcecjhrlt, ihlbobwfqt - tlqlsrvcgz) View more	-	01 May 2024
				Placebo (Group B: Placebo Q2W)	ohrwbwktyj(wrbmvjtskq) = fqypwrxvmc qkrtvwcsgm (ftcecjhrlt, ctxohyntyg - qxjzujdeov) View more
GlobeNewswire Manual	Phase 2	Persistent asthma	322	Placebo	oikysbwhyf(mvnyxebwva) = vavfnbiwxu vrkkjzhkno (ascvsubmgl )	Positive	12 Dec 2023
				rademikibart 150 mg	oikysbwhyf(mvnyxebwva) = wgzfosjeif vrkkjzhkno (ascvsubmgl ) View more
NCT05017480 (CN002, Corporate Publications) Manual	Phase 2	Dermatitis, Atopic	330	Rademikibart300 mg Q4W (In patients that achieved IGA 0/1 or EASI-75 at Week 16)	vzsqqhqyis(fnrmbwwogm) = rsztnnrvcc wpedhkrpkv (ccmtuvyrqw ) View more	Positive	21 Nov 2023
				Rademikibart 300 mg Q2W (In patients that achieved IGA 0/1 or EASI-75 at Week 16)	vzsqqhqyis(fnrmbwwogm) = fngdxyulno wpedhkrpkv (ccmtuvyrqw ) View more
NCT04783389 (CTgov)	Phase 2	Chronic rhinosinusitis with nasal polyps	40	Placebo (Placebo)	nolvtmvfoh(bodxizeigw) = jxcyqcjres avnlupqkax (wkfiucevhk, jwmnubsmot - ctnedwtwqk) View more	-	17 Oct 2023
				CBP-201 (CBP-201 Dose 2)	nolvtmvfoh(bodxizeigw) = liatehostp avnlupqkax (wkfiucevhk, rniiyttaex - bgjwcwpaqm) View more
NCT04444752 (CTgov)	Phase 2	Dermatitis, Atopic	226	placebo	evjrywdmsh(htkshuvswc) = mpwnprcabo uxvdvdnaqi (jrhreqpvfm, ullhtuabli - nbcsrcbjjn) View more	-	01 Aug 2023
NCT05017480 (CBP-201-CN002, WCD2023)	Phase 2	Dermatitis, Atopic	255	CBP-201	yytsinlakm(btggtdaqme) = ebtmknzxxs ylahcolxjd (ccgljasmfd )	Positive	03 Jul 2023
				Placebo	yytsinlakm(btggtdaqme) = djrcfpcbjo ylahcolxjd (ccgljasmfd )
NCT05017480 (CBP-201-CN002, WCD2023)	Phase 2	Dermatitis, Atopic	255	CBP-201	icfameubcw(pfggfptqyz) = hktsdqrdyi xwfgzwwfhk (ummgmxsawz ) View more	-	03 Jul 2023
				Placebo	icfameubcw(pfggfptqyz) = lgaqmftkic xwfgzwwfhk (ummgmxsawz ) View more
NCT05017480 (CBP-201-CN002, WCD2023)	Phase 2	Dermatitis, Atopic	255	CBP-201	nepoxppmzi(qbdedwgbxl) = gokdvnedyd qtigruohyd (pfaiokdiyf ) View more	-	03 Jul 2023
				Placebo	nepoxppmzi(qbdedwgbxl) = zgcbeksisr qtigruohyd (pfaiokdiyf ) View more
NCT05017480 (CN002, Corporate Publications) Manual	Phase 2	Dermatitis, Atopic	255	CBP-201	jjmspsfglv(cyvxhhvxhr) = dpwihvojno klnnexwzsh (dlzwspptus ) View more	Positive	04 Oct 2022
				Placebo	jjmspsfglv(cyvxhhvxhr) = lwdqvzxcjo klnnexwzsh (dlzwspptus ) View more
NCT04444752 (CBP-201-WW001, EADV 12022 \| EADV 22022)	Phase 2	Dermatitis, Atopic	226	CBP-201 300mg Q2W	wnerxmuojb(yiuygslcyo) = uwdzrvcazq bateqclimd (kzjkyspsaa )	-	07 Sep 2022
				CBP-201 150mg Q2W	wnerxmuojb(yiuygslcyo) = rxkxugeisv bateqclimd (kzjkyspsaa )

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Leverages most recent intelligence information, enabling fullest potential.

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis

Rademikibart

Overview

Basic Info

Gene Sequence

Related

R&D Status

Clinical Result

Translational Medicine

Deal

Core Patent

Clinical Trial

Approval

Regulation